Clinical trials: Oral Malignancy
Advanced Non-small Cell Lung Cancer
A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies
This is a Phase I/II, multi-center, open-label study, composed with a Phase I part (dose-escalation phase) followed by a Phase II part (expansion phase).
- Trial name
- NCT02108964
- Testing
- EGF816
- Where
- 14 sites in United States, Canada and 7 more
- Volunteers
- 225 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia
A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT
20010133 is an open-label, dose escalation study in pediatric patients with acute leukemias receiving myelotoxic therapy (high dose etoposide, cyclophosphamide and total body irradiation [TBI]) followed by hematopoietic stem cell…
- Trial name
- NCT00460421
- Testing
- Palifermin, Total Body irradiation, Chemotherapy
- Where
- 7 sites in United States
- Volunteers
- 27 people
- Sponsor
- Swedish Orphan Biovitrum
Lip and Oral Cavity Squamous Cell Carcinoma, Oral Cavity Verrucous Carcinoma
Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions
This randomized phase II trial studies how well vandetanib works in preventing head and neck cancer in patients with precancerous head and neck lesions. Chemoprevention is the use of certain drugs to keep cancer from forming.
- Conditions
- Lip and Oral Cavity Squamous Cell Carcinoma, Oral Cavity Verrucous Carcinoma, Precancerous Condition
- Trial name
- NCT01414426
- Testing
- vandetanib, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Chicago
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma
Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy
This phase II trial studies how well giving temsirolimus together with cetuximab works compared to temsirolimus alone in treating patients with recurrent and/or metastatic head and neck cancer who did not respond to previous…
- Conditions
- Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
- Trial name
- MAESTRO HN (NCT01256385)
- Testing
- Cetuximab, Laboratory Biomarker Analysis, Temsirolimus
- Where
- 24 sites in United States, China
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Green Tea Extract in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia
RATIONALE: Green tea extract contains ingredients that may slow the growth of certain cancers. PURPOSE: This phase I/II trial is studying the side effects and best dose of green tea extract and to see how well it works in…
- Trial name
- NCT00262743
- Testing
- Polyphenon E
- Where
- 2 sites in United States
- Volunteers
- 73 people
- Sponsor
- Mayo Clinic
Head and Neck Cancer
A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer
To investigate the efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer following administration of rebamipide and to determine the optimal dose of rebamipide.
- Trial name
- NCT02085460
- Testing
- 2% Rebamipide liquid, 4% Rebamipide liquid
- Where
- 5 sites in Japan
- Volunteers
- 94 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Pancreatic Cancer
Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas
The primary goal of the research study is to determine whether treating pancreatic cancer patients with hydroxychloroquine in combination with gemcitabine before surgery is safe.
- Trial name
- NCT01128296
- Testing
- Hydroxychloroquine, Gemcitabine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Amer Zureikat
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00939627
- Testing
- cetuximab, sorafenib tosylate, laboratory biomarker analysis
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Refractory Leukemia, Acute Myelogenous Leukemia
Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)
This study was to evaluate the efficacy and safety of single agent oral panobinostat in patients who have refractory de novo or refractory secondary AML.
- Trial name
- NCT00880269
- Testing
- Panobinostat/LBH589
- Where
- 40 sites in United States, Australia and 10 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors, Hematologic Malignancies
Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction
This is a phase 1, 2-part, pharmacokinetic study in patients with advanced solid tumors or hematologic malignancies and varying degrees of liver dysfunction (normal function, moderate hepatic impairement or severe hepatic…
- Trial name
- NCT01912222
- Testing
- IXAZOMIB
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Non-Hodgkin's Lymphoma
Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
The purpose of the study is to find out the effects and the safety of an investigational study drug called LBH589 when given to people with relapsed or refractory chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL).
- Trial name
- NCT01090973
- Testing
- LBH589
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Appendix Carcinoma, Colon Carcinoma
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
This phase II trial investigates how well oral cryotherapy plus acupressure and acupuncture compared with oral cryotherapy alone work in decreasing chemotherapy-induced peripheral neuropathy in patients with gastrointestinal…
- Conditions
- Appendix Carcinoma, Colon Carcinoma, Esophageal Carcinoma, Gastric Carcinoma
- Trial name
- NCT04505553
- Testing
- Acupuncture Therapy, Acupressure Therapy, Oral Cryotherapy
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- University of Washington
Carcinoma, Non-Small-Cell Lung
LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib
The objective of the Phase I step is to estimate the MTD at a dose level up to 50 mg/day (i.e., overseas recommended Phase II dose) in patients with advanced NSCLC and to determine the recommended dose for the Phase II step.
- Trial name
- NCT00711594
- Testing
- BIBW 2992 MA2 40mg/day, BIBW 2992 MA2 50mg/day, BIBW 2992 MA2 20mg/day
- Where
- 20 sites in Japan
- Volunteers
- 74 people
- Sponsor
- Boehringer Ingelheim
Salivary Gland Cancer
Iressa Study in Patients With Salivary Gland Cancer
The goal of this clinical research study is to learn if ZD1839 (Iressa®, gefitinib can help to shrink or slow the growth of advanced, recurrent, or metastatic salivary gland cancer. The safety of this drug will also be studied.
- Trial name
- NCT00509002
- Testing
- Gefitinib
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Hematologic Malignancy, Malignant Lymphoma
Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
The purpose of this study is to evaluate the effect and safety of multiple doses of ketoconazole on the pharmacokinetics of romidepsin after a single intravenous (IV) infusion.
- Trial name
- NCT01324310
- Testing
- Romidepsin, Ketoconazole
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 15 people
- Sponsor
- Celgene
Oral Squamous Cell Carcinoma
Neoadjuvant Imiquimod Immunotherapy for Oral Cancer
The purpose of this research study is to find out what effects, good and/or bad, topical application of the drug Aldara will have on patients and on their oral cancer.
- Trial name
- NCT04883645
- Testing
- Imiquimod 5% Cream
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Medical University of South Carolina
Head and Neck Cancer, Acute Pain
Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients
Patient satisfaction with healthcare is increasingly being utilized as a metric to reflect provider and hospital quality of care.
- Conditions
- Head and Neck Cancer, Acute Pain, Postoperative Pain
- Trial name
- GABA (NCT02926573)
- Testing
- Gabapentin
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- Washington University School of Medicine
Larynx, Lip
Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer
This pilot clinical trial studies how well metformin hydrochloride works in affecting cytokines and exosomes in patients with head and neck cancer.
- Conditions
- Larynx, Lip, Oral Cavity, Pharynx
- Trial name
- NCT03109873
- Testing
- External Beam Radiation Therapy, Metformin Hydrochloride
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Head and Neck Cancer
Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them.
- Trial name
- NCT00301028
- Testing
- Cetuximab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma
Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer
This phase II trial studies the effects of interstitial photodynamic therapy in patients with head and neck cancer that has come back.
- Conditions
- Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary
- Trial name
- NCT02068157
- Testing
- Laboratory Biomarker Analysis, Photodynamic Therapy, Porfimer Sodium
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Roswell Park Cancer Institute